However, the prevalence and prognostic value of PD‐L1 expression levels in advanced NSCLC remains controversial, so does that of CD8+ TILs 26, 27, 28, 29, 30, 31, 32, 33. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.